Sucampo Pharma (SCMP) Tops Q2 EPS by 6c; Boosts FY15 EPS Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.21, $0.06 better than the analyst estimate of $0.15. Revenue for the quarter came in at $34.9 million versus the consensus estimate of $31.9 million.

Sucampo Pharma sees FY2015 EPS of $0.65-$0.75, versus the consensus of $0.62.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance